iX Biopharma Ltd. (SES: 42C.SI) Stock Competitors & Peer Comparison
See 42C.SI's competitors and their performance on the SES and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for 42C.SI and its SES peers.
Stock Comparison
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SES: T14.SI)
42C.SI vs T14.SI Comparison August 2026
iX Biopharma Ltd. (SES: 42C.SI) plays a significant role within the Healthcare sector. Its performance on the SES reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 42C.SI stands at 497.5M. In comparison, T14.SI has a market cap of 3.3B. Regarding current trading prices, 42C.SI is priced at SGD 0.46 on the SES, while T14.SI trades at SGD 2.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
42C.SI currently has a P/E ratio of -38.66, whereas T14.SI's P/E ratio is 6.40. In terms of profitability, 42C.SI's ROE is -2.14%, compared to T14.SI's ROE of +0.11%. Regarding short-term risk, 42C.SI is more volatile compared to T14.SI. This indicates higher risk in terms of short-term price fluctuations for 42C.SI.Check T14.SI's competition here